Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, China, Japan, the other Asia Pacific regions, and internationally. More Details
Adequate balance sheet with limited growth.
Share Price & News
How has Genscript Biotech's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 1548 is more volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: 1548's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
7 Day Return
HK Life Sciences
1 Year Return
HK Life Sciences
Return vs Industry: 1548 underperformed the Hong Kong Life Sciences industry which returned 164.6% over the past year.
Return vs Market: 1548 exceeded the Hong Kong Market which returned 21.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Genscript Biotech's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StIs It Time To Consider Buying Genscript Biotech Corporation (HKG:1548)?
1 month ago | Simply Wall StIs Genscript Biotech Corporation (HKG:1548) Trading At A 49% Discount?
2 months ago | Simply Wall StIs Genscript Biotech (HKG:1548) Using Debt In A Risky Way?
Is Genscript Biotech undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 1548 (HK$34.7) is trading below our estimate of fair value (HK$35.18)
Significantly Below Fair Value: 1548 is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: 1548 is unprofitable, so we can't compare its PE Ratio to the Asian Life Sciences industry average.
PE vs Market: 1548 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 1548's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 1548 is overvalued based on its PB Ratio (9.7x) compared to the HK Life Sciences industry average (9.3x).
How is Genscript Biotech forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1548 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 1548 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 1548 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 1548's revenue (25.7% per year) is forecast to grow faster than the Hong Kong market (12.8% per year).
High Growth Revenue: 1548's revenue (25.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1548 is forecast to be unprofitable in 3 years.
How has Genscript Biotech performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1548 is currently unprofitable.
Growing Profit Margin: 1548 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 1548 is unprofitable, and losses have increased over the past 5 years at a rate of 75.4% per year.
Accelerating Growth: Unable to compare 1548's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1548 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (66.3%).
Return on Equity
High ROE: 1548 has a negative Return on Equity (-34.51%), as it is currently unprofitable.
How is Genscript Biotech's financial position?
Financial Position Analysis
Short Term Liabilities: 1548's short term assets ($993.2M) exceed its short term liabilities ($327.9M).
Long Term Liabilities: 1548's short term assets ($993.2M) exceed its long term liabilities ($303.9M).
Debt to Equity History and Analysis
Debt Level: 1548's debt to equity ratio (5.6%) is considered satisfactory.
Reducing Debt: 1548's debt to equity ratio has increased from 0.02% to 5.6% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 1548 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 1548 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Genscript Biotech current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 1548's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 1548's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 1548's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 1548's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: 1548 is not paying a notable dividend for the Hong Kong market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 1548's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Patrick Liu (44 yo)
Dr. Zhenyu Liu, also known as Patrick, serves as the Chief Executive Officer of Genscript Biotech Corporation since August 2, 2020. He has management experience in the life science and biologics developmen...
Experienced Management: 1548's management team is considered experienced (3.5 years average tenure).
Experienced Board: 1548's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 1548 insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.7%.
Genscript Biotech Corporation's company bio, employee growth, exchange listings and data sources
- Name: Genscript Biotech Corporation
- Ticker: 1548
- Exchange: SEHK
- Founded: 2002
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$69.182b
- Shares outstanding: 2.08b
- Website: https://www.genscript.com
Number of Employees
- Genscript Biotech Corporation
- Jiangning Science Park
- No. 28, Yongxi Road
- Jiangsu Province
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, China, Japan, the other Asia Pacif...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/24 10:18|
|End of Day Share Price||2021/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.